Lupin Limited announced the achievement of key milestones for Lupins MEK inhibitor compound (LNP3794) that is planned for development by Boehringer Ingelheim in combination as potential targeted therapy for patients with difficult-to-treat cancers.
As part of the agreement, Lupin has received payment of USD 50 million from Boehringer Ingelheim
for achievement of key milestones.
- Read more about Lupin Announces Achievement of Key Milestones for its Clinical Stage MEK Inhibitor Compound
- Log in or register to post comments
source https://www.pharmatutor.org/pharma-news/2021/lupin-announces-achievement-of-key-milestones-for-its-clinical-stage-mek-inhibitor-compound
No comments:
Post a Comment